Cost per median overall survival month for abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Pilon, Dominic
Lefebvre, Patrick
Queener, Marykay
Ellis, Lorie
机构：
[1] Grp Anal Ltee, Montreal, PQ, Canada
[2] Janssen Sci Affairs LLC, Horsham, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16080
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ABIraterone (ABI) and ENZalutamide (ENZ) induce changes in immunologic profile of patients with metastatic castration-resistant prostate cancer (mCRPC)
    Salgia, Meghan
    Perez, Marc L.
    Jones, Jeremy
    Won, Hae Jung
    Poroyko, Valeriy
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Pal, Sumanta K.
    CANCER RESEARCH, 2017, 77
  • [42] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
  • [43] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [44] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [45] Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)
    Pal, Sumanta Kumar
    Patel, Jaymala
    He, Miaoling
    Foulk, Brad
    Kraft, Katherine
    Smirnov, Denis A.
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Bhargava, Vipul
    Jones, Jeremy O.
    CANCER, 2018, 124 (06) : 1216 - 1224
  • [46] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [47] Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
    Di Lorenzo, Giuseppe
    Sonpavde, Guru
    Pond, Gregory
    Lucarelli, Giuseppe
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Carteni, Giacomo
    Federico, Piera
    Daniele, Bruno
    Morelli, Franco
    Bellelli, Teresa
    Ferro, Matteo
    De Placido, Sabino
    Buonerba, Carlo
    EUROPEAN UROLOGY FOCUS, 2018, 4 (06): : 874 - 879
  • [48] Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.
    Wilson, Robert
    Doherty, Jason M.
    Luo, Suhong
    Candelieri-Surette, Danielle
    Eaton Jr, Daniel B.
    Schoen, Martin W.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [49] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [50] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
12345